Shaoxian Tang, Baohua Yu, Xiaoli Xu, Yufan Cheng, Xiaoyu Tu, Hongfen Lu, Rui Bi, Xiangjie Sun, Ruohong Shui, Wentao Yang
Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
J Clin Pathol. 2017 Nov;70(11):926-934. doi: 10.1136/jclinpath-2016-204137. Epub 2017 Apr 20.
GATA-binding protein 3 (GATA3) is a sensitive and relatively specific marker in breast and urothelial carcinomas. Its diagnostic utility in primary and metastatic breast cancers has been explored and confirmed. However, the relationship between GATA3 expression and different breast carcinoma intrinsic subtypes has not been specifically defined in the literature despite a few reports with a small number of cases. The aim of the current investigation is to clarify GATA3 expression among different histological subtypes and surrogate molecular breast carcinoma subtypes in a large series of cases.
Immunohistochemical staining of GATA3, GCDFP15 and mammaglobin was performed in a cohort of 1637 cases of primary invasive breast carcinoma. The association of GATA3 expression with different histological and surrogate intrinsic subtypes was assessed and compared with the expression of GCDFP15 and mammaglobin.
The overall positivity of GATA3 across the various immunohistochemistry-based surrogate intrinsic subtypes was 99.51% for luminal A-like, 97.70% for luminal B-like, 68.50% for HER2 overexpression and 20.16% for triple negative breast cancers. GATA3 expression was positively correlated with estrogen receptor (ER)-positive (luminal subtypes) breast carcinomas. For luminal-like and HER2 overexpression subtypes, GATA3 was much more sensitive than GCDFP15 and mammaglobin. For triple negative tumours, GATA3 was less sensitive than GCDFP15.
GATA3 exhibits a relatively high sensitivity for breast carcinomas. It is more sensitive than GCDFP15 and mammaglobin in luminal-like and HER2 overexpression subtypes. GATA3 expression is associated with breast carcinomas of luminal subtype and low histological grade.
GATA结合蛋白3（GATA3）是乳腺癌和尿路上皮癌中一种敏感且相对特异的标志物。其在原发性和转移性乳腺癌中的诊断效用已得到探索和证实。然而，尽管有少数关于少量病例的报道，但GATA3表达与不同乳腺癌内在亚型之间的关系在文献中尚未明确界定。本研究的目的是在大量病例中阐明不同组织学亚型和替代分子乳腺癌亚型中GATA3的表达情况。
对1637例原发性浸润性乳腺癌病例进行GATA3、GCDFP15和乳腺珠蛋白的免疫组织化学染色。评估GATA3表达与不同组织学和替代内在亚型的相关性，并与GCDFP15和乳腺珠蛋白的表达进行比较。
在基于免疫组织化学的各种替代内在亚型中，GATA3的总体阳性率在腔面A型样为99.51%，腔面B型样为97.70%，HER2过表达型为68.50%，三阴性乳腺癌为20.16%。GATA3表达与雌激素受体（ER）阳性（腔面亚型）乳腺癌呈正相关。对于腔面样和HER2过表达亚型，GATA3比GCDFP15和乳腺珠蛋白更敏感。对于三阴性肿瘤，GATA3比GCDFP15敏感性低。
GATA3对乳腺癌表现出相对较高的敏感性。在腔面样和HER2过表达亚型中，它比GCDFP15和乳腺珠蛋白更敏感。GATA3表达与腔面亚型乳腺癌及低组织学分级相关。
